Avrobio Plots Plan B After Fabry Disease Gene Therapy Problems
Lead Candidate Shelved
Avrobio is sidestepping market and regulatory issues in Fabry disease by suspending development of AVR-RD-01, but says it remains focused on advancing treatment of lysosomal storage disorders with gene therapies.
You may also be interested in...
The lentiviral gene therapy company is still trading below cash, but the cystinosis results add extra momentum to its comeback.
Early data in Gaucher disease suggest Avrobio’s hematopoietic stem cell gene therapy could help patients who do not response to enzyme replacement therapy.
Avrobio dropping out of the race means Sangamo can take advantage but its gene therapy must show long-term efficacy in patients not receiving enzyme replacement therapy.